Inhibitors, namely shikonin and its analogs lapachol, lead to reduced glycolysis and increased necroptosis and apoptosis in human breast cancer cells and melanoma cells [92, 93], supporting PKM2 as a potential TGF-dependent glycolysis target for cancer therapy. This evidence concerns the gene PKM and cancer.